跳转至内容
Merck
CN

N0590200

(-)-尼古丁 酒石酸氢盐

European Pharmacopoeia (EP) Reference Standard

别名:

(-)-1-甲基-2-(3-吡啶基)吡咯烷 (+)-酒石酸氢盐

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C10H14N2 · 2C4H6O6
化学文摘社编号:
分子量:
462.41
NACRES:
NA.24
UNSPSC Code:
41116107
EC Number:
200-607-2
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


grade

pharmaceutical primary standard

API family

nicotine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CN1CCC[C@H]1C2=CC=CN=C2.C

InChI

1S/C10H14N2.CH4/c1-12-7-3-5-10(12)9-4-2-6-11-8-9;/h2,4,6,8,10H,3,5,7H2,1H3;1H4/t10-;/m0./s1

InChI key

RYYKFQGHMYGLEL-PPHPATTJSA-N

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Nicotine ditartrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

原型烟酸乙酰胆碱受体激动剂;天然异构体。

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.


Still not finding the right product?

Explore all of our products under (-)-尼古丁 酒石酸氢盐


signalword

Danger

Hazard Classifications

Acute Tox. 2 Inhalation - Acute Tox. 3 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - Repr. 2

存储类别

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 2

flash_point_f

289.8 °F

flash_point_c

143.2 °C

法规信息

涉药品监管产品

此项目有



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Gabriel Quiroz et al.
Frontiers in pharmacology, 10, 1429-1429 (2019-12-19)
Brain nicotinic acetylcholine receptors (nAChRs), a heterogeneous family of pentameric acetylcholine-gated cation channels, have been suggested as molecular targets for the treatment of alcohol abuse and dependence. Here, we examined the effect of the competitive nAChR antagonist UFR2709 on the
José-Rubén García-Montes et al.
Molecular neurobiology, 56(6), 4037-4050 (2018-09-28)
L-DOPA is the main pharmacological therapy for Parkinson's disease. However, long-term exposure to L-DOPA induces involuntary movements termed dyskinesia. Clinical trials show that dyskinesia is attenuated by metabotropic glutamate receptor type 5 (mGluR5) antagonists. Further, the onset of dyskinesia is
Elizabeth B Rex et al.
SLAS discovery : advancing life sciences R & D, 22(2), 155-165 (2016-10-30)
Cellular signaling is in part regulated by the composition and subcellular localization of a series of protein interactions that collectively form a signaling complex. Using the α7 nicotinic acetylcholine receptor (α7nAChR) as a proof-of-concept target, we developed a platform to



全球贸易项目编号

货号GTIN
N059020004061834092926